Acute promyelocytic leukemia overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 8: Line 8:
In APL, there is an abnormal accumulation of immature [[granulocytes]] called promyelocytes.  The disease is characterized by a [[chromosomal translocation]] involving the [[retinoic acid receptor]] alpha (''RARα'' or ''RARA'') gene and is unique from other forms of AML in its responsiveness to [[ATRA|all ''trans'' retinoic acid]] (ATRA) therapy.
In APL, there is an abnormal accumulation of immature [[granulocytes]] called promyelocytes.  The disease is characterized by a [[chromosomal translocation]] involving the [[retinoic acid receptor]] alpha (''RARα'' or ''RARA'') gene and is unique from other forms of AML in its responsiveness to [[ATRA|all ''trans'' retinoic acid]] (ATRA) therapy.


==Historical perspective==
==Historical Perspective==
The first documentation of the successful treatment of acute promyelocytic leukemia occurred in the late 19th century, at which time physicians and scientists explored the role of [[arsenic]] as an anti-leukemic agent. Since that time, multiple advances have been made over the years. Specifically, the use of cytotoxic chemotherapy ([[anthracycline]] and [[cytarabine]]) has been explored extensively. The use of [[all-''trans'' retinoic acid]] in the 20th century has revolutionized the treatment paradigm for acute promyelocytic leukemia. In the early 21st century, a landmark study showed that the combination of [[arsenic trioxide]] plus [[all-''trans'' retinoic acid]] was superior to [[conventional chemotherapy]] for low-risk acute promyelocytic leukemia.
The first documentation of the successful treatment of acute promyelocytic leukemia occurred in the late 19th century, at which time physicians and scientists explored the role of [[arsenic]] as an anti-leukemic agent. Since that time, multiple advances have been made over the years. Specifically, the use of cytotoxic chemotherapy ([[anthracycline]] and [[cytarabine]]) has been explored extensively. The use of [[all-''trans'' retinoic acid]] in the 20th century has revolutionized the treatment paradigm for acute promyelocytic leukemia. In the early 21st century, a landmark study showed that the combination of [[arsenic trioxide]] plus [[all-''trans'' retinoic acid]] was superior to [[conventional chemotherapy]] for low-risk acute promyelocytic leukemia.



Revision as of 08:07, 27 May 2018

Acute promyelocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute promyelocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary PreventionSurgery

Secondary PreventionSurgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute promyelocytic leukemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute promyelocytic leukemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute promyelocytic leukemia overview

CDC on Acute promyelocytic leukemia overview

Acute promyelocytic leukemia overview in the news

Blogs on Acute promyelocytic leukemia overview

Directions to Hospitals Treating Acute promyelocytic leukemia

Risk calculators and risk factors for Acute promyelocytic leukemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Acute promyelocytic leukemia is a subtype of acute myelogenous leukemia (AML), a cancer of the blood and bone marrow.

In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARα or RARA) gene and is unique from other forms of AML in its responsiveness to all trans retinoic acid (ATRA) therapy.

Historical Perspective

The first documentation of the successful treatment of acute promyelocytic leukemia occurred in the late 19th century, at which time physicians and scientists explored the role of arsenic as an anti-leukemic agent. Since that time, multiple advances have been made over the years. Specifically, the use of cytotoxic chemotherapy (anthracycline and cytarabine) has been explored extensively. The use of all-''trans'' retinoic acid in the 20th century has revolutionized the treatment paradigm for acute promyelocytic leukemia. In the early 21st century, a landmark study showed that the combination of arsenic trioxide plus all-''trans'' retinoic acid was superior to conventional chemotherapy for low-risk acute promyelocytic leukemia.

Classification

There are several broad classification schemes for acute promyelocytic leukemia. The most well-accepted classification scheme is risk-based classification, which categories patients into low-risk, intermediate-risk, or high-risk based on the white blood cell count and platelet count. Another classification scheme is based on the origin of the leukemia, which categorized patients as having de novo or therapy-related disease. A final classification scheme is cytogenetic-based, in which case specific chromosomal abnormalities are used to stratify patients.

References

Template:WH Template:WS